ArticleJournal of cosmetic dermatology2026
Non-Surgical Hip Augmentation With a PDLLA-Hyaluronic Acid.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHip contouring is experiencing growing demand within aesthetic medicine, a trend particularly pronounced in Asian populations where cultural preferences emphasize harmoniously proportioned feminine silhouettes. While surgical augmentation remains an option, its inherent procedural risks and protracted recovery periods underscore the need for effective minimally invasive alternatives. Volumetric enhancement using biostimulatory agents, such as poly-D,L-lactic acid (PDLLA), constitutes a non-surgical approach.
objectiveThis study aimed to evaluate the safety, efficacy, and patient satisfaction of bilateral hip augmentation using PDLLA in a cohort of Korean women.
methodsA prospective case series was conducted involving 30 Korean women (age range: 24-48 years). Participants underwent bilateral hip augmentation between January and June 2024 using a PDLLA-HA hybrid biostimulator (Juvelook G[export name: Juvelook GLAM]). The mean total volume administered was 201.5 mL (range: 180-220 mL; approximately 100 mL per side, range: 90-110 mL). Outcomes were assessed using the Global Aesthetic Improvement Scale (GAIS), patient satisfaction scores (0-10 scale), and standardized photography at the 6-month follow-up.
resultsAll 30 participants completed the study protocol. No significant adverse events were reported. Mean patient satisfaction at 6 months was 8.7/10 (±0.9 SD). Based on GAIS assessments, 27 participants (90%) demonstrated moderate to significant aesthetic improvement. Minor transient complications included swelling (n = 13, 43.3%) and mild discomfort (n = 8, 26.7%), all resolving spontaneously within 1 week.
conclusionsPDLLA hip augmentation, using total volumes approximating 200 mL, demonstrates a favorable safety profile and high efficacy in this cohort of Korean women. The results indicate this approach presents a viable minimally invasive alternative to conventional surgical implant procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.